Inhibitex, Inc. Has Agreed to be Acquired by Bristol-Myers Squibb Company

  • Do you own shares of Inhibitex, Inc. (Nasdaq: INHX)?
  • Did you buy any shares before January 7, 2012?
  • Do you think that the proposed buyout price is too low?
  • Do you want to discuss your rights?

If the answer to these questions is "yes," please contact the deal lawyers at Rigrodsky & Long, P.A. ("R & L") today to schedule a FREE consultation. Just call us, or fill out our contact form so that we can call at your convenience. Your consultation will not create any obligation to use our services at any time.

Contact R & L today to be sure your best interests are being protected.

R & L is national law firm with decades of combined legal experience. R & L is investigating potential claims against the board of directors of Inhibitex, Inc. concerning possible breaches of fiduciary duty and other violations of law related to the Company’s entry into an agreement to be acquired by Bristol-Myers Squibb Company for approximately $2.5 billion.

Click here to read the full press release.

Rigrodsky & Long, P.A. Investigates Inhibitex, Inc.'s Sale to Bristol-Myers Squibb Company for Shareholders

Rigrodsky & Long, P.A. announces that it is investigating potential claims against the board of directors of Inhibitex, Inc. (“Inhibitex” or the “Company”) (Nasdaq: INHX) concerning possible breaches of fiduciary duty and other violations of law related to the Company’s entry into an agreement to be acquired by Bristol-Myers Squibb Company (“Bristol-Myers”) in a transaction with an approximate value of $2.5 billion.

Under the proposed agreement, Bristol-Myers Squibb will commence a cash tender offer to purchase all of the outstanding shares of Inhibitex’s common stock for $26.00 per share.

The investigation concerns whether Inhibitex’s board of directors adequately shopped the Company to obtain the best price possible for Inhibitex shareholders before entering into the agreement with Bristol-Myers.  Indeed, shareholders with beneficial ownership of approximately 17% of Inhibitex’s common stock have already entered into agreements with Bristol-Myers to support the transaction and to tender their shares in the tender offer.

If you own the common stock of Inhibitex and purchased your shares before January 7, 2012, if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Seth D. Rigrodsky, Esquire or Noah R. Wortman, Case Development Director, of Rigrodsky & Long, P.A., 919 N. Market Street, Suite 980, Wilmington, Delaware 19801, by telephone at (888) 969-4242, or by e-mail to info@rigrodskylong.com.

Rigrodsky & Long, P.A., with offices in Wilmington, Delaware and Garden City, New York, regularly litigates securities class, derivative and direct actions, shareholder rights litigation and corporate governance litigation, including claims for breach of fiduciary duty and proxy violations in the Delaware Court of Chancery and in state and federal courts throughout the United States.

Attorney advertising.  Prior results do not guarantee a similar outcome.

R & L, with offices in Delaware and New York, litigates securities class, derivative and direct actions, shareholder rights litigation and corporate governance litigation, including claims for breach of fiduciary duty and proxy violations in the Delaware Court of Chancery and in state and federal courts throughout the United States.

Attorney advertising.  Prior results do not guarantee a similar outcome.

Learn more about R&L:  Visit Our Website |  Our Firm  |  Our Practice Areas  |  FAQ's

Fill out the form below or call us toll-free at 888-969-4242, for a FREE no-obligation consultation.